Trial Condition(s):

Colorectal Neoplasms

Stivarga Regulatory Post-Marketing Surveillance Study in Korea (StivargaPMS)

Bayer Identifier:

16778

ClinicalTrials.gov Identifier:

NCT02106858

EudraCT Number:

Not Available

Study Completed

Trial Purpose

To investigate and collect post-marketing data on the safety of Stivarga in real world practice in its registered indication(s) as required by Health Authority.

Inclusion Criteria
- Signed and dated informed consent
- Patients diagnosed with histologically confirmed metastatic colorectal cancer and/or metastatic or unresectable locally advanced gastrointestinal stromal tumors and/or HCC who have been previously treated with sorafenib by physician
- Patients who are prescribed with Stivarga tablet 40mg(Regorafenib) for the first time
 
-
Exclusion Criteria
- Patients participating in an investigational program with interventions outside of routine clinical practice
- All contra-indications according to the local marketing authorization have to be considered.

Trial Summary

Enrollment Goal
316
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Stivarga (Regorafenib, BAY73-4506)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, South Korea

Status
Recruiting
 

Trial Design